NASDAQ: ATYR - aTyr Pharma, Inc.

Yield per half year: +77.84%
Dividend yield: 0.00%
Sector: Healthcare

Share chart aTyr Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

more details
The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2015-05-07
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.atyrpharma.com
Цена ао 3.24
Change price per day: -3.99% (3.26)
Change price per week: -14.95% (3.68)
Change price per month: -19.12% (3.87)
Change price per 3 month: -16.31% (3.74)
Change price per half year: +77.84% (1.76)
Change price per year to date: +1.62% (3.08)
All parameters

Underestimation

Title Value Grade
P/S 1143.94 1
P/BV 3.85 4
P/E 0 0
EV/EBITDA -4.08 0
Total: 3.25

Efficiency

Title Value Grade
ROA, % -58.88 0
ROE, % -79.69 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2001 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -97.76 0
Yield Ebitda, % 353.22 10
Yield EPS, % -41.45 0
Total: 6
More



Head Job title Payment Year of birth
Dr. Sanjay S. Shukla M.D., M.S. President, CEO & Director 1972 (53 years)
Ms. Jill M. Broadfoot Chief Financial Officer 1962 (63 years)
Ms. Nancy E. Denyes Krueger General Counsel & Corporate Secretary 1968 (57 years)
Xiang-Lei Yang Ph.D. Founder
Dr. Jayant Aphale MBA, Ph.D. Vice President of Technical Operations 1960 (65 years)
Ms. Ashlee Dunston Director of Investor Relations & Corporate Communications
Mr. Peter Villiger Vice President of Corporate Development
Ms. Danielle Campbell VP of Human Resource
Dr. Leslie Nangle Ph.D. Vice President of Research
Dr. Ying J. Buechler Ph.D. Executive Director of Biologics Development & Manufacturing

Address: United States, San Diego, 10240 Sorrento Valley Road - open in Google maps, open in Yandex maps
Website: https://www.atyrpharma.com